GHK-Cu: the copper peptide and skin biology
A look at the tripeptide that's drawn sustained attention in dermatology research — and why.
TL;DR
- GHK-Cu is glycyl-L-histidyl-L-lysine bound to copper — a tripeptide found naturally in human plasma that declines with age.
- Laboratory and ex vivo research has linked it to collagen-synthesis gene expression and extracellular matrix remodeling.
- Most data comes from cell culture and animal models; controlled human trials are limited — important context before drawing conclusions.
What it is
GHK-Cu stands for glycyl-L-histidyl-L-lysine copper. It is a naturally occurring tripeptide — a chain of just three amino acids (glycine, histidine, lysine) bound to a copper ion. Human plasma concentrations fall with age, according to work by Loren Pickart, who first isolated and characterized the molecule in the 1970s. That age-related decline made GHK-Cu a subject of sustained interest in dermatology and wound-healing research.
How it works
In lab studies, GHK-Cu interacts with a range of cellular pathways involved in tissue repair. The copper ion is central: it acts as a cofactor for enzymes including lysyl oxidase, which cross-links collagen and elastin fibers in the extracellular matrix (ECM). In cell studies, the peptide portion appears to help carry copper into cells and to change the expression of genes related to matrix remodeling.
The histidine residue is particularly important for copper chelation — it binds the Cu²⁺ ion and stabilizes the complex, preventing free copper from generating oxidative byproducts.
Who asks about it
People researching GHK-Cu are usually looking at two overlapping questions: does the age-related decline in plasma GHK-Cu have practical relevance for skin maintenance, and does it matter whether GHK-Cu is applied to the skin or injected? These are reasonable questions, and the research differs by route of delivery — a topic covered separately.
What the research says
Pickart's 2018 review in the International Journal of Molecular Sciences summarized decades of research on GHK-Cu across wound healing, ECM remodeling, and gene-expression studies. In ex vivo skin models and cell culture, GHK-Cu has been associated with upregulation of collagen genes, as well as modulation of matrix metalloproteinases (MMPs) — enzymes involved in ECM breakdown and remodeling. In animal wound-healing studies described in the review, treated wounds healed faster than controls. The key caveat is that the majority of evidence is preclinical. Rigorous, randomized controlled trials in humans remain limited. The research supports continued investigation; it does not show that GHK-Cu works in people.
What to know
Topical and injectable forms deliver the peptide via fundamentally different mechanisms with different pharmacokinetics — route matters, and research on one route does not carry over to the other. Controlled human trials are limited, so safety and effectiveness in people have not been established.
The Halftime POV
GHK-Cu is one of the more studied skin-related peptides in the published literature. The gap between what ex vivo science shows and what's confirmed in controlled human trials is real, and we think it's worth naming directly. At Halftime, we'd rather you understand exactly what the research says — and what it doesn't — than oversell what a compound can do.
Related reading:
FAQ
Q: What is GHK-Cu? A: GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It declines with age. Published research has studied it in the context of dermal collagen synthesis, wound healing, and skin remodeling in cell culture and animal models.
Q: How does GHK-Cu work in skin? A: GHK-Cu is studied for its interactions with matrix metalloproteinases (MMPs) and collagen gene expression in dermal fibroblasts. Published cell-culture research describes upregulation of collagen genes and modulation of MMP activity. Most data is in vitro or from ex vivo skin models, not large-scale human trials.
Q: What is GHK-Cu's FDA status? A: FDA removed injectable GHK-Cu from Category 2 on April 22, 2026, after its nomination was withdrawn. FDA has not approved GHK-Cu, and FDA has not decided whether pharmacies may compound it (see the FDA status note on this page). This page does not cover obtaining it. Cosmetic GHK-Cu serums are a different product category, with a different regulatory status.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences, 2018
- Pickart L. "The human tri-peptide GHK and tissue remodeling." Journal of Biomaterials Science, 2008
Frequently asked questions
What is GHK-Cu?
GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. It declines with age. Published research has studied it in the context of dermal collagen synthesis, wound healing, and skin remodeling in cell culture and animal models.
How does GHK-Cu work in skin?
GHK-Cu is studied for its interactions with matrix metalloproteinases (MMPs) and collagen gene expression in dermal fibroblasts. Published cell-culture research describes upregulation of collagen genes and modulation of MMP activity. Most data is in vitro or from ex vivo skin models, not large-scale human trials.
What is GHK-Cu's FDA status?
FDA removed injectable GHK-Cu from Category 2 on April 22, 2026, after its nomination was withdrawn. FDA has not approved GHK-Cu, and FDA has not decided whether pharmacies may compound it (see the FDA status note on this page). This page does not cover obtaining it. Cosmetic GHK-Cu serums are a different product category, with a different regulatory status.
